The Safety and Efficacy of Autologous Transfusion in Spinal Surgery for Lung Cancer With Spinal Metastasis

Launched by GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL · Jan 28, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a method called autologous blood transfusion during spinal surgery for patients with lung cancer that has spread to the spine. Essentially, this means that patients may donate their own blood before surgery, which can be used to help them during and after the operation. The trial aims to find out if using a patient’s own blood helps prevent new cancer growth, affects important blood levels after surgery, and reduces the need for blood from other donors.

To participate in the trial, patients need to be between 18 and 75 years old and have been diagnosed with lung cancer that has spread to their spine. They should also be expected to live for more than three months and be able to handle surgery. However, patients with serious heart issues, blood disorders, or severe kidney problems won’t be eligible. If you join the trial, you can expect to have your own blood collected before the surgery and closely monitored afterwards to see how well this approach works compared to traditional blood transfusions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • The age range is 18-75 years old;
• • The pathological diagnosis was lung cancer and spinal metastatic tumor;
• • Expected survival \> 3 months, can tolerate surgery;
• • Unstable spine; And/or spinal cord nerve compression, nerve function; Progressive decline, palliative spinal open decompression surgery
• • Patients with intraoperative/postoperative Hb\<90 g/L or other conditions requiring blood transfusion
• Exclusion Criteria:
• • Serious heart dysfunction or heart failure, diagnosed blood system diseases, coagulation disorders;
• • Severe renal insufficiency or need hemodialysis treatment;
• • Sepsis or septicemia;
• • Unable to obtain consent from the patient or family.